About
Overview
Leadership
Area of Focus
Congestion in Heart Failure
Outpatient Parenteral Antimicrobial Treatment (OPAT)
Research and Development
FUROSCIX® (furosemide) 80 mg/10 mL for subcutaneous administration
scCeftriaxone
Clinical Development & Medical Affairs
Investor Relations
Investor Overview
Stock Information
Stock Quote & Chart
Historical Price Lookup
Investment Calculator
Corporate Governance
Governance Highlights
Committee Composition
Financial Information
Sec Filings
News & Events
News Releases
Event Calendar
Presentations
Investor Resources
Investor FAQ
Information Request
E-mail Alerts
Ir Contacts
Media Resources
Careers
Contact Us
Legal
Privacy Policy
Terms of Use
scPharmaceuticals
Areas of Focus
Research & Development
Careers
Recent News
August 09, 2022
scPharmaceuticals Inc. Reports Second Quarter 2022 Financial Results and Provides Business Update
Read More
July 13, 2022
scPharmaceuticals Inc. to Participate in the Maxim Group LLC Late-Stage Advancements in Heart Failure Therapeutics and Management Panel Discussion
Read More
July 12, 2022
scPharmaceuticals Inc. Announces Positive Results from the AT HOME-HF Phase 2 Pilot Study in Heart Failure
Read More
June 30, 2022
scPharmaceuticals Inc. to Host FUROSCIX
®
(furosemide) 80mg/10mL for Subcutaneous Administration Commercial Day: An Investigational Treatment for Heart Failure Patients
Read More
All News
